Efficacy and Safety of Cilostazol for the Indication of CSPS

Completed

Phase 4 Results N/A

Trial Description

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Detailed Description

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.
Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Conditions

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Probability Sample

Trial Population

Patients in restabilization status after cerebral infarction (excluding cardiogenic cerebral embolism)

Outcomes

Type Measure Time Frame Safety Issue
Primary 1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event 3M Yes

Sponsors